The Medical Letter on Drugs and Therapeutics
FROM
ISSUE 1503
ISSUE 1503
September 12, 2016
Issue 1503
- Byvalson - A Beta Blocker/ARB Combination for Hypertension
- Daclizumab (Zinbryta) for Multiple Sclerosis
- In Brief: Defibrotide (Defitelio) for Hepatic Veno-Occlusive Disease
- In Brief: Repatha Pushtronex - A New Evolocumab Injection Device
- In Brief: Epinephrine Auto-Injectors for Anaphylaxis (online only)
Subscribers: Log in to read full issue. Not a subscriber? Subscribe or purchase issue.
Byvalson - A Beta Blocker/ARB Combination for Hypertension
September 12, 2016 (Issue: 1503)
The FDA has approved Byvalson (Allergan), a fixed-dose
combination of the beta blocker nebivolol
(Bystolic) and the angiotensin receptor blocker (ARB)
valsartan (Diovan, and generics), for treatment of
hypertension. It is the only combination...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.